Rafferty Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-17,325
| Closed | -$85.2K | – | 1203 |
|
|
2024
Q1 | $85.2K | Sell |
17,325
-11,255
| -39% | -$55.4K | ﹤0.01% | 1074 |
|
|
2023
Q4 | $251K | Buy |
28,580
+8,089
| +39% | +$71.1K | ﹤0.01% | 1043 |
|
|
2023
Q3 | $235K | Buy |
20,491
+11,478
| +127% | +$132K | ﹤0.01% | 1042 |
|
|
2023
Q2 | $228K | Buy |
9,013
+1,964
| +28% | +$49.7K | ﹤0.01% | 1068 |
|
|
2023
Q1 | $227K | Sell |
7,049
-5,531
| -44% | -$178K | ﹤0.01% | 1088 |
|
|
2022
Q4 | $232K | Buy |
+12,580
| New | +$232K | ﹤0.01% | 1056 |
|
|
2022
Q3 | – | Sell |
-12,793
| Closed | -$177K | – | 1271 |
|
|
2022
Q2 | $177K | Buy |
+12,793
| New | +$177K | ﹤0.01% | 1048 |
|
|
2022
Q1 | – | Sell |
-14,724
| Closed | -$240K | – | 1340 |
|
|
2021
Q4 | $240K | Buy |
14,724
+6,923
| +89% | +$113K | ﹤0.01% | 1189 |
|
|
2021
Q3 | $217K | Buy |
+7,801
| New | +$217K | ﹤0.01% | 1181 |
|
|
2021
Q1 | – | Sell |
-7,912
| Closed | -$224K | – | 1173 |
|
|
2020
Q4 | $224K | Buy |
+7,912
| New | +$224K | ﹤0.01% | 959 |
|